CD274 and neoplasm: Although the prognostic implications of PD-L1 expression specifically on tumor cells versus immune cells within MPE remain unresolved, this case demonstrates that ivonescimab can yield substantial clinical benefit in a patient with tumor cell-positive PD-L1 expression.